A rating of 83 puts Adaptimmune Therapeutics PLC - ADR (ADAP) near the top of the Biotechnology industry according to InvestorsObserver. Adaptimmune Therapeutics PLC - ADR's score of 83 means it scores higher than 83% of stocks in the industry. Adaptimmune Therapeutics PLC - ADR also received an overall rating of 66, putting it above 66% of all stocks. Biotechnology is ranked 26 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Adaptimmune Therapeutics PLC - ADR (ADAP) stock is down -5.53% while the S&P 500 is up 0.31% as of 1:26 PM on Friday, Aug 28. ADAP is lower by -$0.45 from the previous closing price of $8.14 on volume of 849,165 shares. Over the past year the S&P 500 is higher by 19.52% while ADAP is up 380.63%. ADAP lost -$1.10 per share the over the last 12 months.

To screen for more stocks like ADAP click here.

Original post:
Should You Buy Adaptimmune Therapeutics PLC - ADR (ADAP) in Biotechnology Industry? - InvestorsObserver